首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2030篇
  免费   176篇
  国内免费   21篇
耳鼻咽喉   11篇
儿科学   30篇
妇产科学   24篇
基础医学   331篇
口腔科学   22篇
临床医学   255篇
内科学   465篇
皮肤病学   61篇
神经病学   81篇
特种医学   88篇
外科学   239篇
综合类   22篇
一般理论   1篇
预防医学   209篇
眼科学   82篇
药学   171篇
中国医学   6篇
肿瘤学   129篇
  2023年   24篇
  2022年   78篇
  2021年   145篇
  2020年   51篇
  2019年   86篇
  2018年   80篇
  2017年   41篇
  2016年   60篇
  2015年   63篇
  2014年   98篇
  2013年   101篇
  2012年   152篇
  2011年   133篇
  2010年   68篇
  2009年   68篇
  2008年   110篇
  2007年   113篇
  2006年   94篇
  2005年   89篇
  2004年   86篇
  2003年   74篇
  2002年   60篇
  2001年   47篇
  2000年   38篇
  1999年   34篇
  1998年   14篇
  1997年   11篇
  1996年   19篇
  1995年   8篇
  1994年   7篇
  1993年   9篇
  1992年   23篇
  1991年   17篇
  1990年   16篇
  1989年   12篇
  1988年   22篇
  1987年   13篇
  1986年   11篇
  1985年   17篇
  1984年   7篇
  1983年   8篇
  1982年   4篇
  1980年   2篇
  1979年   3篇
  1976年   1篇
  1975年   2篇
  1972年   1篇
  1969年   1篇
  1968年   4篇
  1964年   1篇
排序方式: 共有2227条查询结果,搜索用时 15 毫秒
31.
32.
33.
34.
We hypothesized that the use of stents and aggressive adjunctive pharmacotherapies has been associated with lower rates of complicating myocardial infarction (MI) and improved long-term outcomes compared to either previous balloon-only percutaneous coronary intervention (PCI) or atheroablative intervention for lesions of or through saphenous vein grafts (SVGs) and/or internal mammary arteries (IMAs). PCI of SVG has been complicated by relatively high rates of procedural MI and less favorable long-term outcomes than native vessel PCI, stimulating the development and application of an array of technologies. This study was based on retrospective review of stent-era (1999-2004) 5-year experience of a single center with 95 SVG procedures in 85 patients and 20 IMA procedures in 20 patients. These cases were compared with the previously published experience of one of the operators during the balloon-only period and literature review of the application of multiple technologies to SVG intervention, as well as consideration of the reoperation alternative. There was one in-hospital death each in the SVG cohort (1%) and in the IMA cohort (5%). There were SIX procedural MIs (6%), defined by total CK > normal, and 19 procedural MIs (20%) based on troponin-I > 1.0. Follow-up has been from 4 months to 5 years (average, 2.5 years), with 91% survival and one late CABG in the IMA group. SVG PCI with stents and adjunctive pharmacotherapies is associated with relatively low rates of procedural MI and favorable long-term outcomes.  相似文献   
35.
36.
37.
38.
39.
Hu  JP; Cesano  A; Santoli  D; Clark  SC; Hoang  T 《Blood》1993,81(6):1586-1592
Interleukin-11 (IL-11) is a pleiotropic cytokine with effects on many different targets. Within the hematopoietic system, the effects of IL- 11 are largely manifest only through combination with other cytokines, including IL-3 and Steel factor (SF). In the present study, we addressed the question of IL-11 responsiveness within the different types of human leukemic cells, as well as the mechanism of action of IL- 11 at the cellular level. Analysis of a panel of samples from different patients with acute myeloblastic leukemia (AML) and myeloid leukemic cell lines indicated that IL-11 alone was ineffective in supporting myeloid leukemic cell growth but frequently enhanced growth supported by IL-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), or SF. In contrast, three acute pre-B lymphocytic leukemia (pre-B-ALL) and two acute T lymphocytic leukemia (T-ALL) lines failed to respond to IL- 11 alone or when combined with other cytokines. The growth enhancement of IL-11 among the AML patient samples was dose dependent and remarkably constant with half-efficient concentrations in the range of 0.3 to 0.4 ng/mL. The thymidine suicide studies with the patient samples revealed that 40% to 50% of the blast cells were in S-phase when exposed for 16 hours to IL-3 and this level was increased to 70% to 90% in response to either IL-11 or IL-6. Our data suggest that the latter two interleukins act synergistically with the direct mitogenic factor, IL-3, in triggering AML blast-cell proliferation. Detailed analysis with several patient samples further revealed that SF and IL- 11 both enhance IL-3-supported clonogenic growth of AML blasts and the combination of all three growth factors yields optimal growth. In contrast, IL-6 does not further enhance the effect of IL-11. These results indicate that SF and IL-11 enhance IL-3-dependent clonogenic growth through two distinct pathways, whereas IL-6 and IL-11 may trigger the same pathway.  相似文献   
40.
The properties of melting are required for the prediction of solubility of solid compounds. Unfortunately, direct determination of the enthalpy of fusion and melting temperature by using conventional DSC or adiabatic calorimetry is often not possible for biological compounds due to decomposition during the measurement. To overcome this, fast scanning calorimetry (FSC) with scanning rates up to 2 × 104 K s−1 was used in this work to measure the melting parameters for l-alanine and glycine. The enthalpy of fusion and melting temperature (extrapolated to zero heating rate) were ΔfusH = (22 ± 5) kJ mol−1 and Tfus = (608 ± 9) K for l-alanine, and ΔfusH = (21 ± 4) kJ mol−1 and Tfus = (569 ± 7) K for glycine. These melting properties were used in the modeling framework PC-SAFT to predict amino-acid solubility in water. The pure-component PC-SAFT parameters and one binary parameter were taken from literature, in which these parameters were fitted to solubility-independent thermodynamic properties such as osmotic coefficients or mixture densities. It was shown that this allowed accurately predicting amino-acid solubility in water over a broad temperature range. The combined methodology of PC-SAFT and FSC proposed in this work opens the door for predicting solubility of molecules that decompose before melting.

New experimental melting properties combined with PC-SAFT allow quantitative solubility predictions of amino acids in water.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号